SARS-COV-2 COURSE and OUTCOME in PATIENTS with SYSTEMIC AUTOINFLAMMATORY DISEASES (SAID) TREATED with IL-1 INHIBITORS and COLCHICINE
Annals of the Rheumatic Diseases
; 81:940, 2022.
Article
in English
| EMBASE | ID: covidwho-2008910
abatacept; anakinra; canakinumab; colchicine; endogenous compound; interleukin 1; methotrexate; vaccine; adult; adult onset Still disease; adverse drug reaction; autoinflammatory disease; case report; clinical article; clinical feature; cohort analysis; conference abstract; coronavirus disease 2019; coughing; cytokine release; drug combination; drug therapy; e-mail; employment; fatality; female; fever; gastrointestinal symptom; human; male; nonhuman; outcome assessment; outpatient department; recurrent fever; reinfection; sample size; Schnitzler syndrome; Severe acute respiratory syndrome coronavirus 2; telephone
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS